Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Marti Masso

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Electroencephalography and Clinical Neurophysiology|July 1, 1980
Somatosensory evoked potentials: abnormalities with focal brain lesions remote from the primary sensorimotor areaJ A Obeso, J F Marti-Masso, N Carrera
Neurology|February 1, 1993
Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristicsS S Junger, B J Stern, S R Levine, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1980
Neurophysiological assessment of alpha pattern comaJ A Obeso, M I Iragui, J F Marti-Masso, et al.
Drugs|March 4, 1998
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study GroupU K Rinne, F Bracco, C Chouza, et al.
Journal of the Neurological Sciences|November 1, 1979
Conduction velocity through the somesthetic pathway in chronic renal failureJ A Obeso, J F Marti-Masso, J L Asin, et al.
Parkinsonism & Related Disorders|August 16, 2014
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2A Estanga, M C Rodriguez-Oroz, J Ruiz-Martinez, et al.
Neurology|February 1, 1997
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study GroupU K Rinne, F Bracco, C Chouza, et al.
European Journal of Neurology|January 20, 2017
Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's diseaseK Brockmann, C Schulte, N Schneiderhan-Marra, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Electroencephalography and Clinical Neurophysiology|July 1, 1980
Somatosensory evoked potentials: abnormalities with focal brain lesions remote from the primary sensorimotor areaJ A Obeso, J F Marti-Masso, N Carrera
Neurology|February 1, 1993
Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristicsS S Junger, B J Stern, S R Levine, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1980
Neurophysiological assessment of alpha pattern comaJ A Obeso, M I Iragui, J F Marti-Masso, et al.
Drugs|March 4, 1998
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study GroupU K Rinne, F Bracco, C Chouza, et al.
Journal of the Neurological Sciences|November 1, 1979
Conduction velocity through the somesthetic pathway in chronic renal failureJ A Obeso, J F Marti-Masso, J L Asin, et al.
Parkinsonism & Related Disorders|August 16, 2014
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2A Estanga, M C Rodriguez-Oroz, J Ruiz-Martinez, et al.
Neurology|February 1, 1997
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study GroupU K Rinne, F Bracco, C Chouza, et al.
European Journal of Neurology|January 20, 2017
Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's diseaseK Brockmann, C Schulte, N Schneiderhan-Marra, et al.
Pageof 1